Department of Cardiac Surgery, Heartcentre Leipzig, Leipzig, Germany.
Clinic for Cardiac Surgery, University of Turin, Turin, Italy.
J Am Coll Cardiol. 2014 Mar 11;63(9):914-9. doi: 10.1016/j.jacc.2013.07.090. Epub 2013 Sep 24.
The goal of this study was to evaluate the safety and performance of the NeoChord DS1000 system (NeoChord, Inc., Minneapolis, Minnesota).
There is an increasing interest in transcatheter mitral valve (MV) treatment. The NeoChord DS 1000 system enables off-pump beating heart transapical MV repair with implantation of artificial neo-chordae.
Patients with severe mitral regurgitation (MR) due to isolated posterior prolapse were included in this TACT (Transapical Artificial Chordae Tendinae) trial. All patients were scheduled for off-pump transapical implantation of neo-chordae.
Thirty patients at 7 centers were enrolled. Major adverse events included 1 death due to post-cardiotomy syndrome and concomitant sepsis and 1 minor stroke with the patient fully recovered at the 30-day follow-up visit. Additional patients experienced procedural major adverse events related to a reoperation or conversion to standard of care. Acute procedural success (placement of at least 1 neo-chord and reduction of MR from 3+ or 4+ to ≤2+) was achieved in 26 patients (86.7%). In 4 patients neo-chordae were not placed for technical and/or patient-specific reasons. These patients underwent intraoperative (3 patients) or post-operative (1 patient) standard MV repair. At 30 days, 17 patients maintained an MR grade ≤2+. Four patients who developed recurrent MR were successfully treated with open MV repair during 30-day follow-up. Results improved with experience: durable reduction in MR to ≤2+ at 30 days was achieved in 5 (33.3%) of the first 15 patients and 12 (85.7%) of the last 14 patients.
Off-pump transapical implantation of artificial chordae to correct MR is technically safe and feasible; however, it yields further potential for improvement of efficacy and durability. (Safety and Performance Study of the NeoChord Device [TACT]; NCT01777815).
本研究旨在评估 NeoChord DS1000 系统(NeoChord,Inc.,明尼苏达州明尼阿波利斯市)的安全性和性能。
经导管二尖瓣(MV)治疗的兴趣日益增加。NeoChord DS 1000 系统通过经心尖植入人工新腱索实现非体外循环跳动心脏 MV 修复。
本 TACT(经心尖人工腱索)试验纳入了因孤立性后瓣脱垂而患有严重二尖瓣反流(MR)的患者。所有患者均计划进行非体外循环经心尖植入新腱索。
在 7 个中心共纳入 30 例患者。主要不良事件包括 1 例因心脏手术后综合征合并败血症导致的死亡和 1 例轻微中风,患者在 30 天随访时完全康复。其他患者经历了与再次手术或转为标准治疗相关的程序主要不良事件。26 例(86.7%)患者达到急性程序成功(至少植入 1 根新腱索,MR 从 3+或 4+减少至≤2+)。4 例患者因技术和/或患者特异性原因未植入新腱索。这些患者在术中(3 例)或术后(1 例)接受了标准 MV 修复。30 天时,17 例患者维持 MR 分级≤2+。4 例出现复发性 MR 的患者在 30 天随访期间成功接受了开放式 MV 修复。经验的增加改善了结果:在最初的 15 例患者中有 5 例(33.3%)和最后 14 例患者中有 12 例(85.7%)在 30 天时达到了 MR 持久减少至≤2+。
经心尖非体外循环植入人工腱索纠正 MR 在技术上是安全可行的,但在疗效和持久性方面还有进一步提高的潜力。(NeoChord 装置的安全性和性能研究[TACT];NCT01777815)。